解锁下一个水平的蛋白质降解

Early learnings centered on how this new approach of generating molecules (degradomers) could hijack the body’s system of turning over proteins and carrying them to the trash chute, Vasudevan says.

自从发现degradomers -分子降解细胞内蛋白质AbbVie团队建造了他们的专业知识和现在侧重于建立一个更广泛的可持续发展的平台,可重复的和可伸缩的不同治疗领域,根据Vasudevan,博士,我们的高级主管,发现平台技术和全球degradomer主管工作。

早期经验集中在这个新方法生成分子(degradomers)可以劫持身体的系统将蛋白质和携带他们的垃圾槽,Vasudevan说。

Protein degradation does something else entirely, says Vasudevan, which is to degrade the desired protein from the system. This approach allows scientists to target a larger part of the human proteome, since degradomers can attach anywhere on a protein and not just a certain site.

Protein degradation has potential in many disease areas, including oncology, immunology and neurology by aiming to selectively eliminating disease associated proteins, says Steve Elmore, Ph.D., vice president, drug discovery science & technology, AbbVie.

“Harnessing the potential of targeted protein degradation has unlocked a whole new world for us as scientists, and also for the people with conditions and diseases many thought were untreatable,” Elmore says. “Our culture of exploration and curiosity has helped us drive forward this work the past several years.”

科学家长期以来依靠一种方法影响蛋白质在细胞和治疗疾病,抑制其功能绑定到一个特定的网站。

Vasudevan说,蛋白质降解是完全不同的东西,也就是降低从系统所需的蛋白质。这种方法允许科学家的目标更大的人类蛋白质组的一部分,因为degradomers可以附加任何一种蛋白质,而不仅仅是某个网站。

蛋白质降解有潜力在许多疾病领域,包括肿瘤学、免疫学和神经学旨在选择性地消除疾病相关的蛋白质,博士,副总裁史蒂夫·爱尔摩说药物发现科技、AbbVie。

“利用潜在的目标蛋白质降解为我们开启了一个全新的世界作为科学家,也为条件和疾病患者很多人认为是无法治愈的,“爱尔摩说。“我们文化的探索和好奇帮助我们推进这项工作过去几年。”

As part of this wave, Vasudevan and his group began conducting initial experiments in the lab. Violeta Marin, Ph.D., senior scientist, discovery platform technologies, recalls going to Vasudevan’s office along with her colleagues in the early days and brainstorming around potential approaches on the whiteboard.

A chemical biologist by trade, she helped establish a path to leverage chemical matter and bring the theory to life, deriving a playbook for protein degradation.

Today, this area of science is being explored across the industry. At AbbVie, what was a small group of scientists working around them has since expanded to a robust, strategic team that spans discovery, development sciences, clinical and corporate strategy, with core members across therapeutic and functional areas.

This second wave of innovation is around how to selectively degrade proteins in certain tissues or organs, like proteins in immune cells only, Vasudevan says. Additionally, AbbVie is researching how to impact hard-to-treat disease areas, like neuroscience.

“The application of protein degradation to targets in neuroscience we care about requires degradomers to get into the brain,” Vasudevan says. “We’re focused on technologies and collaborations that allow us to better deliver to the brain.”

理解退化的细微差别,包括如果真的能做的方式最终会导致新疗法,代表创新的第一波在前几年,Vasudevan说。

作为这一波的一部分,Vasudevan教授和他的团队开始在实验室进行初步实验。Violeta马林,博士,资深科学家,发现平台技术,回忆Vasudevan办公室以及她的同事们在早期和头脑风暴在潜在的方法在白板上。

化学生物学家通过贸易,她帮助建立一个路径,利用化学物质和给生活带来理论,推导蛋白降解的剧本。

今天,这个行业正在探索的科学领域。AbbVie,周围是一小群科学家研究已经扩展到一个健壮的、跨越战略团队发现,发展科学,临床和公司战略,核心成员在治疗和功能区域。狗万正网地址

这第二波的创新是如何选择性地降解蛋白质在某些组织或器官,如蛋白质的免疫细胞,Vasudevan说。此外,AbbVie正在研究如何影响不易治愈的疾病领域,像神经科学。

在神经科学”蛋白质降解的应用目标我们关心要求degradomers进入大脑,“Vasudevan说。“我们专注于技术和合作,让我们更好地传递到大脑。”